Menu Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring. doDOC is an innovative, best-in-class, Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today. While customers will have the choice to deploy doDOC standalone, the solution will be seamlessly integrated with Envision’s leading medical affairs platform, iEnvision. This unlocks the huge potential for customers to allow real time in-line editing of medical affairs documents, delivering efficiency gains of around 70% versus document processes without doDOC. Founded in 2015 in Boston, MA, with a European base in Coimbra, Portugal, the company will operate as a business unit under its current brand and will continue to be led by doDOC CEO and co-founder, Federico Cismondi. David Thompson, CEO, Envision, said, “Bringing doDOC into the Envision family enables us to continue to increase our innovative technology offerings to support life science companies’ goals in becoming ever more efficient and effective in the communication of key scientific data. doDOC is the standout company in its field and, critically, shares our values and commitment to working collaboratively to provide smart solutions that ensure our clients’ success. It will also allow us to consider developing capabilities that enable us to spread beyond our medical affairs client base, including supporting client commercial activities.” “Envision’s acquisition of doDOC is great for our customers and employees. It allows doDOC to join a proven medical affairs technology leader and advance our solutions for the industry,” said Federico Cismondi, CEO, doDOC. “Most importantly, our companies share a commitment to provide industry-leading innovate solutions and to work together in a collaborative way to ensure our customers’ success.” Manish Goel, Global Head of Envision Technology Solutions, added, “With our first clients now live on an integrated doDOC and iEnvision platform, we have a capability that no one else in the market can credibly claim as part of their solution. With doDOC as part of Envision Pharma Group, we can broaden our technology capabilities, creating efficiencies for clients and adding value as a strategic partner to deepen our client relationships.” Dot grid. Related news View all news Our growing presence in Japan and the Asia-Pacific region News/events Our growing presence in Japan and the Asia-Pacific region August 30, 2017 Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running News/events Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running August 26, 2017 Envision Pharma Group announces the availability of Scopus citation counts in Datavision News/events Envision Pharma Group announces the availability of Scopus citation counts in Datavision April 24, 2017 Envision announces Altmetric attention data now available in Library™ scientific content management software News/events Envision announces Altmetric attention data now available in Library™ scientific content management software April 24, 2017 Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information News/events Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information March 20, 2017 iEnvision Contact us ISO/IEC 27001 Certification Twitter LinkedIn © 2001-2020 Envision Pharma Group. All rights reserved. Terms of use Privacy notice Cookies notice Privacy shield policy Modern slavery statement We use cookies on our website. By continuing to use this website, you consent to our use of cookies in accordance with our cookie policy. To learn more about cookies, how we use them, and how you can change your settings, please view our Cookies Notice Accept